Design characteristics of the CORRONA CERTAIN study: A comparative effectiveness study of biologic agents for rheumatoid arthritis patients

BMC Musculoskeletal Disorders

Volumn 15, Issue 1, 2014, Pages

  Pappas, Dimitrios A ^a,b   Kremer, Joel M ^c   Reed, George ^b,d   Greenberg, Jeffrey D ^b,e   Curtis, Jeffrey R ^f  

^a Columbia University College of Physicians and Surgeons ^*  (United States)

^b Departments of Biostatistics and Epidemiology and Outcomes Research   (United States)

^c Center for Rheumatology LLP   (United States)

^d UNIVERSITY OF MASSACHUSETTS   (United States)

^e New York School of Medicine   (United States)

^f The University of Alabama at Birmingham   (United States)

Author keywords

Biologics; Cohort; Comparative effectiveness; Epidemiology; Registry; Rheumatoid arthritis; Safety

Indexed keywords

ABATACEPT; ADALIMUMAB; BIOLOGICAL PRODUCT; CERTOLIZUMAB PEGOL; ETANERCEPT; GOLIMUMAB; HYDROXYCHLOROQUINE; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; PREDNISONE; RITUXIMAB; SALAZOSULFAPYRIDINE; TOCILIZUMAB; TUMOR NECROSIS FACTOR INHIBITOR;

ADULT; ARTICLE; BLOOD ANALYSIS; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DISEASE ACTIVITY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; NORTH AMERICA; PHYSICIAN; RHEUMATOID ARTHRITIS; RHEUMATOLOGY; SCIENTIST;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; COHORT STUDIES; ENDPOINT DETERMINATION; HUMANS; MULTICENTER STUDIES AS TOPIC; PATIENT SELECTION; PHARMACOGENETICS; PROSPECTIVE STUDIES; QUALITY ASSURANCE, HEALTH CARE; REGISTRIES; RESEARCH DESIGN; RHEUMATOLOGY; TUMOR NECROSIS FACTOR-ALPHA; UNITED STATES;

EID: 84898420424     PISSN: None     EISSN: 14712474     Source Type: Journal    
DOI: 10.1186/1471-2474-15-113     Document Type: Article

References (26)

1. Department of Health and Human Services: comparative effectiveness funding. [ http://www.effectivehealthcare.ahrq.gov/index.cfm/comparative- effectiveness-research-grant-and-arra-awards/ ]
2. Health care reform and the need for comparative-effectiveness research. Mushlin AI, Ghomrawi H, N Engl J Med 2010 362 6 10.1056/NEJMp0912651 20054035
3. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, Smolen JS, Weisman M, Emery P, Feldmann M, Harriman GR, Maini RN, Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group, N Engl J Med 2000 343 1594 1602 10.1056/NEJM200011303432202 11096166 (Pubitemid 32162982)
4. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Klareskog L, van der Heijde D, de Jager JP, Gough A, Kalden J, Malaise M, Martin Mola E, Pavelka K, Sany J, Settas L, Wajdula J, Pedersen R, Fatenejad S, Sanda M, investigators Ts, Lancet 2004 363 675 681 10.1016/S0140-6736(04)15640-7 15001324 (Pubitemid 38296553)
5. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Breedveld FC, Weisman MH, Kavanaugh AF, Cohen SB, Pavelka K, van Vollenhoven R, Sharp J, Perez JL, Spencer-Green GT, Arthritis Rheum 2006 54 26 37 10.1002/art.21519 16385520 (Pubitemid 43122183)
6. The efficacy of anti-TNF in rheumatoid arthritis, a comparison between randomised controlled trials and clinical practice. Kievit W, Fransen J, Oerlemans AJ, Kuper HH, van der Laar MA, de Rooij DJ, De Gendt CM, Ronday KH, Jansen TL, van Oijen PC, Brus HL, Adang EM, van Riel PL, Ann Rheum Dis 2007 66 1473 1478 10.1136/ard.2007.072447 17426065 (Pubitemid 350032655)
7. Tumor necrosis factor antagonist responsiveness in a United States rheumatoid arthritis cohort. Greenberg JD, Kishimoto M, Strand V, Cohen SB, Olenginski TP, Harrington T, Kafka SP, Reed G, Kremer JM, Consortium of Rheumatology Researchers of North America I, Am J Med 2008 121 532 538 10.1016/j.amjmed.2008.02.018 18501236 (Pubitemid 351694340)
8. Effectiveness of tumor necrosis factor inhibitors in rheumatoid arthritis in an observational cohort study: comparison of patients according to their eligibility for major randomized clinical trials. Zink A, Strangfeld A, Schneider M, Herzer P, Hierse F, Stoyanova-Scholz M, Wassenberg S, Kapelle A, Listing J, Arthritis Rheum 2006 54 3399 3407 10.1002/art.22193 17075823 (Pubitemid 44737150)
9. Eligibility of patients in routine care for major clinical trials of anti-tumor necrosis factor alpha agents in rheumatoid arthritis. Sokka T, Pincus T, Arthritis Rheum 2003 48 313 318 10.1002/art.10817 12571838 (Pubitemid 36277997)
10. Biologic drugs for rheumatoid arthritis in the Medicare program: a cost-effectiveness analysis. Wailoo AJ, Bansback N, Brennan A, Michaud K, Nixon RM, Wolfe F, Arthritis Rheum 2008 58 939 946 10.1002/art.23374 18383356 (Pubitemid 351563994)
11. Kaiser Permanente's evaluation and management of biotech drugs: assessing, measuring, and affecting use. Monroe CD, Potter L, Millares M, Barrueta A, Wagner R, Health Aff 2006 25 1340 1346 10.1377/hlthaff.25.5.1340 (Pubitemid 44497634)
12. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Officers A, Coordinators for the ACRGTA, Lipid-Lowering Treatment to Prevent Heart Attack T, JAMA 2002 288 2981 2997 10.1001/jama.288.23.2981 12479763 (Pubitemid 35471160)
13. The CORRONA database. Kremer JM, Autoimmun Rev 2006 5 46 54 10.1016/j.autrev.2005.07.006 16338211 (Pubitemid 41759442)
14. Assessment of coxib utilization by rheumatologists for nonsteroidal antiinflammatory drug gastroprotection prior to the coxib market withdrawals. Greenberg JD, Bingham CO 3rd, Abramson SB, Reed G, Kishimoto M, Hinkle K, Kremer J, Arthritis Rheum 2006 55 543 550 10.1002/art.22095 16874798 (Pubitemid 44289872)
15. Effect of cardiovascular comorbidities and concomitant aspirin use on selection of cyclooxygenase inhibitor among rheumatologists. Greenberg JD, Bingham CO 3rd, Abramson SB, Reed G, Sebaldt RJ, Kremer J, Arthritis Rheum 2005 53 12 17 10.1002/art.20905 15696570 (Pubitemid 40216346)
16. Association of methotrexate and tumour necrosis factor antagonists with risk of infectious outcomes including opportunistic infections in the CORRONA registry. Greenberg JD, Reed G, Kremer JM, Tindall E, Kavanaugh A, Zheng C, Bishai W, Hochberg MC, Investigators C, Ann Rheum Dis 2010 69 380 386 10.1136/ard.2008.089276 19359261
17. The COX-2 inhibitor market withdrawals and prescribing patterns by rheumatologists in patients with gastrointestinal and cardiovascular risk. Greenberg JD, Fisher MC, Kremer J, Chang H, Rosenstein ED, Kishimoto M, Lee S, Yazici Y, Kavanaugh A, Abramson SB, Investigators C, Clin Exp Rheumatol 2009 27 395 401 19604430
18. Evaluation of composite measures of treatment response without acute-phase reactants in patients with rheumatoid arthritis. Greenberg JD, Harrold LR, Bentley MJ, Kremer J, Reed G, Strand V, Rheumatology 2009 48 686 690 10.1093/rheumatology/kep054 19395544
19. Prevalence of low hemoglobin levels and associations with other disease parameters in rheumatoid arthritis patients: evidence from the CORRONA registry. Furst DE, Chang H, Greenberg JD, Ranganath VK, Reed G, Ozturk ZE, Kremer JM, Clin Exp Rheumatol 2009 27 560 566 19772785
20. Physician preference motivates the use of anti-tumor necrosis factor therapy independent of clinical disease activity. Curtis JR, Chen L, Harrold LR, Narongroeknawin P, Reed G, Solomon DH, Arthritis Care Res 2010 62 101 107 10.1002/acr.20020
21. Validity of physician-reported hospitalized infections in a US arthritis registry. Curtis JR, Patkar NM, Jain A, Greenberg J, Solomon DH, Rheumatology 2009 48 1269 1272 10.1093/rheumatology/kep205 19654217
22. The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): a review of their usefulness and validity in rheumatoid arthritis. Aletaha D, Smolen J, Clin Exp Rheumatol 2005 23 100 108 16273793
23. Prioritizing comparative-effectiveness research-IOM recommendations. Iglehart JK, New Engl J Med 2009 361 325 328 10.1056/NEJMp0904133 19567828
24. Generalizability of a U.S. Rheumatoid Arthritis Registry: a Comparison Of Participants vs. Non-Participants' Characteristics. Curtis JR, Chen L, Yun H, Harrold LR, Greenberg J, Kremer J, Book Generalizability of a U.S. Rheumatoid Arthritis Registry: A Comparison Of Participants vs. Non-Participants' Characteristics (Editor ed. Eds.), vol. 65. pp. S447 2013 447
25. Does comparative-effectiveness research threaten personalized medicine? Garber AM, Tunis SR, New Engl J Med 2009 360 1925 1927 10.1056/NEJMp0901355 19420360
26. Comparative effectiveness research and genomic medicine: an evolving partnership for 21st century medicine. Khoury MJ, Rich EC, Randhawa G, Teutsch SM, Niederhuber J, Gen Med 2009 11 707 711 10.1097/GIM.0b013e3181b99b90